Diabetes and Obesity Drugs

Swedish researchers at Karolinska Institutet and Stockholm University report in Cell that a novel oral beta-2 agonist improved glucose control and fat burning while preserving muscle in animals, and showed favorable safety/tolerability in a small human study of 48 healthy adults and 25 people with type 2 diabetes. Acting via muscle metabolism rather than appetite suppression like GLP-1s, the drug could be used alone or alongside GLP-1 therapies, though experts stress larger, longer trials are needed to confirm efficacy and long‑term safety.